Assuming they had results. It does seem too close to be a coincidence, so I hope that's the case. :P However, it's possible CYTK scheduled presentation with bad data in hand, so never say never to the idea that company's choose to present failed trial... In CYTK's defense, a bad trial like they just reported isn't the end of the line, but for RMTI it certainly would be for SFP.
There's a big difference between the two. CYTK presented their P2 study in a Cardiology scientific conference. RMTI will be presenting in an investors conference. How will they convince potential investors if their trial failed?